Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for XIST returned no results
Showing 1501 to 1515 of 1558 results for list

  1. Indoor air quality at home (NG149)

    This guideline covers indoor air quality in residential buildings. It aims to raise awareness of the importance of good air quality in people's homes and how to achieve this.

  2. Fremanezumab for preventing migraine (TA764)

    Evidence-based recommendations on fremanezumab (Ajovy) for preventing migraine in adults.

  3. NICE-wide topic prioritisation: the manual (PMG46)

    This manual sets out the process for how new guidance topics and updates to existing NICE guidance are identified, prioritised and routed at NICE, and the decision-making framework used by the NICE prioritisation board

  4. The NxStage System One NX1000‑1 home haemodialysis device for renal replacement therapy in chronic kidney disease (MIB12)

    NICE has developed a medtech innovation briefing (MIB) on The NxStage System One NX1000-1 home haemodialysis device for renal replacement therapy in chronic kidney disease .

  5. The NICE public health guidance development process (third edition) (PMG5)

    This manual describes how public health guidance is produced, and explains the stages of guidance development, the different activities, roles and responsibilities of different groups of people involved at different stages

  6. Child abuse and neglect (NG76)

    This guideline covers recognising and responding to abuse and neglect in children and young people aged under 18. It covers physical, sexual and emotional abuse, and neglect. The guideline aims to help anyone whose work brings them into contact with children and young people to spot signs of abuse and neglect and to know how to respond. It also supports practitioners who carry out assessments and provide early help and interventions to children, young people, parents and carers.

  7. Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)

    This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.

  8. Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

    Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.

  9. Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)

    Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.

  10. Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

  11. Autoimmune haemolytic anaemia: rituximab (ESUOM39)

    Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

  12. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA887)

    Evidence-based recommendations on olaparib (Lynparza) for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer in adults.

  13. The SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of the biliary system (MIB21)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of

  14. Epilepsies in children, young people and adults (NG217)

    This guideline covers diagnosing and managing epilepsy in children, young people and adults in primary and secondary care, and referral to tertiary services. It aims to improve diagnosis and treatment for different seizure types and epilepsy syndromes, and reduce the risks for people with epilepsy.

  15. Sofosbuvir for treating chronic hepatitis C (TA330)

    Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)